2 active not recruiting. 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 2 | Active not recruiting 2 |
Follow Nephritis: new trials by email Literature Review of Nephritis trials Research Report on Nephritis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis Sparsentan - Proteinuria, Immunoglobulin A (IgA) Nephropathy | Phase 4 | Active not recruiting | Travere Therapeutics, Inc. | 20 | 2025-10-07 | 2026-06-23 |
| Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy TARPEYO® - IgA Nephropathy | Phase 4 | Active not recruiting | Calliditas Therapeutics AB | 60 | 2024-12-17 | 2026-09-24 |
Glomerulonephritis, IGA (1) · Glomerulosclerosis, Focal Segmental (1) · Kidney Diseases (1) · Kidney Failure, Chronic (1) · Proteinuria (1)
Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Glomerulonephritis (2) · Male Urogenital Diseases (2) · Pathological Conditions, Signs and Symptoms (2) · Urogenital Diseases (2) · Urologic Diseases (2) · Autoimmune Diseases (1) · Chronic Disease (1) · Disease Attributes (1) · Immune System Diseases (1) · Kidney Diseases (1) · Pathologic Processes (1) · Renal Insufficiency (1)
Budesonide (1) · sparsentan (1)
Calliditas Therapeutics AB (1) · Travere Therapeutics, Inc. (1)
United States (2) · Puerto Rico (1)
Krassimir Mitchev (1) · Radko Komers, MD, PhD (1)